Shalby Ltd. · NSE:SHALBY
Shalby — Q1 FY2022 Earnings Presentation
25 slides from Shalby's earnings presentation, Aug 9, 2021
Slide 1: Exchange filing cover letter for investor presentation
August 9,2021 The Listing Department Corporate Service Department National Stock Exchange of India Ltd BSE Limited Mumbai 400 051. Mumbai 400 001. Scrip Code :SHALBY Scrip Code: 540797 Through : htt~s://www.connect2nse.com/LISTING/ Through : http://listing.bseindia.com Sub: lnvestor Presentation for
Slide 2: Fit for the Future - Q1 FY2022 Earnings Presentation
FIT FOR THE EARNINGS PRESENTATION FUTURE 27 years of serving Q1 FY2022 www.shalby.org
Slide 3: Content
CONTENT 01 Q1 FY2022 PERFORMANCE HIGHLIGHTS 02 SHALBY CONSENSUS UPDATE 03 HOSPITAL BUSINESS UPDATE 04 SUSTAINABILITY INITATIVES 2
Slide 4: Q1 FY2022 Performance Highlights
Q1 FY2022 PERFORMANCE HIGHLIGHTS Delivered highest ever quarterly EBITDA and Net Profit of Rs. 45 Crore and 25 Crore respectively In Patient Count (Nos.) Surgeries Count 9,934 2,813 Total Income Operating EBITDA 3,664 in Q1 FY21 843 in Q1 FY21 Rs. 1,828 mn Rs. 446 mn Beds Occupied (Nos.) Avg. Occupa
Slide 5: Q1 FY2022 Performance Highlights
Q1 FY2022 PERFORMANCE HIGHLIGHTS Shalby continues to deliver strong growth on a sequential basis EBITDA of Rs. 45 crore, up 1.3x and EPS of Rs. 2.30 up by 2.3x over previous quarter • During the quarter, there was a rise in Covid-19 patients due to the second wave of the pandemic and Shalby treated
Slide 6: Management Perspective
MANAGEMENT PERSPECTIVE Commenting on strategy, Mr. Sushobhan Commenting on performance, Mr. Shanay Shah, Dasgupta, Vice Chairman and Global President: President Said: “In Q1 FY2022, Shalby delivered total income of Rs. 1,828 million, an “The first quarter of fiscal year saw an unfortunate resurgence
Slide 7: Covid-19 Vaccination Drive
COVID-19 VACCINATION DRIVE “Shalby stands with the nation amidst the ongoing health pandemic and is committed to the cause of vaccination for the larger good of the society. We treat this as our social and moral responsibility and will ensure no additional cost has to be borne by people and there is
Slide 8: Strengthening and Diversifying Service Offerings
STRENGTHENING AND DIVERSIFYING SERVICE OFFERINGS Strengthening Core Healthcare Service Offerings Business and Geographic Expansion Investing in State-of-the-art Technologies and Digitalization • Launched ‘Shalby institute of Cardiac Sciences (SICS)’ at Indore • Continuous Technology Adaptation: On-b
Slide 9: Q1 FY2022 Performance Highlights
Q1 FY2022 PERFORMANCE HIGHLIGHTS Total Income (Rs. Mn) EBITDA (Rs. Mn) and Margin 1,828 28.0% 24.5% 24.0% 24.4% 1,440 446 1,317 1,118 323 346 314 408 (25) Q1 FY21 Q2 FY21 Q3 FY21 Q4 FY21 Q1 FY22 Q1 FY21 Q2 FY21 Q3 FY21 Q4 FY21 Q1 FY22 PBT (Rs. Mn) and Margin PAT (Rs. Mn) and Margin 19.2% 19.3% 16.9%
Slide 10: Q1 FY2022 Performance Highlights
Q1 FY2022 PERFORMANCE HIGHLIGHTS In Patients count was primarily driven by increase in Covid-19 patients and Surgery count was impacted due to second wave of the pandemic resulting in lower ARPOB In Patients Count Day Care Patients Count Out Patients Count 9,934 5,829 1,04,508 1,03,371 8,945 8,665 5
Slide 11: Q1 FY2022 Performance Highlights
Q1 FY2022 PERFORMANCE HIGHLIGHTS No of Bed Occupied Occupancy Rate* 723 59% 537 45% 489 481 41% 40% 205 17% Q1 FY21 Q2 FY21 Q3 FY21 Q4 FY21 Q1 FY22 Q1 FY21 Q2 FY21 Q3 FY21 Q4 FY21 Q1 FY22 ALOS Revenue Mix by Care 5.94 6.10 5.52 16% 11% 10% 12% 10% 2% 5.10 4% 3% 3% 5.00 7% 77% 85% 86% 85% 88% Q1 FY21
Slide 12: Q1 FY2022 Performance Highlights
Q1 FY2022 PERFORMANCE HIGHLIGHTS Revenue by Hospital Specialty 50% 27% 22% 15% 14% 12% 9% 10% 8% 7% 7% 7% 4% 3% 3% 2% Critical Care & Arthroplasty Oncology Orthopaedic Neurology Cardiac Science Nephrology Others General Medicine Q1 FY21 Q1 FY22 Number of Surgeries by Specialty Revenues by Payer Mix
Slide 13: Q1 FY2022 Performance Highlights
Q1 FY2022 PERFORMANCE HIGHLIGHTS Total Income to EBITDA Bridge 18.0% EBITDA % 28.0% 24.5% 24.0% 24.4% 21.6% Other Expenses % 7.4% 7.3% 7.7% 7.0% 2.9% 12.2% 11.7% 11.0% 12.6% 1.6% 1.5% 1.6% Employee Benefit Expenses % 1.6% 63.7% Purchase and Change in Inventory % 50.3% 54.4% 55.0% 56.1% Operative and
Slide 14: Q1 FY2022 Performance Highlights
Q1 FY2022 PERFORMANCE HIGHLIGHTS Particulars (in Rs. Million) Q1 FY22 Q1 FY21 Y-o-Y Growth Q4 FY21 Q-o-Q Growth Revenue from Operations 1,801 384 369.4% 1,417 27.1% Other Income 27 24 9.4% 23 16.6% Total Income 1,828 408 347.9% 1,440 27.0% Expenses COGS 1,052 272 287.3% 815 29.1% % of Revenue 58% 71
Slide 15: Q1 FY2022 Performance Highlights
Q1 FY2022 PERFORMANCE HIGHLIGHTS Operational Metrics Q1 FY22 Q1 FY21 Y-o-Y Growth Q4 FY21 Q-o-Q Growth In Patient Count 9,934 3,664 171.1% 8,665 14.6% (Nos.) Day Care Patient Count 5,108 3,763 35.7% 5,829 (12.4)% (Nos.) Out Patient Count 1,03,371 32,305 220.0% 1,04,508 (1.1)% (Nos.) Surgeries Count
Slide 16: Shalby Consensus - Q1 FY22
SHALBY CONSENSUS – Q1 FY22 Shalby recently acquired selected implant assets from Consensus Orthopedics for a cash consideration of USD 11.45 million Shalby Advanced Technologies Overview Shalby Limited • Mr. Daniel Hayes, former CEO and founder of Consensus, has been appointed as CEO of Shalby Advan
Slide 17: Shalby Consensus - Q1 FY22
SHALBY CONSENSUS – Q1 FY22 Dedicated management committed to turnaround implant business • Implant business has been operationalized from 14th May, 2021 USD INR Particulars (‘000) (‘000) • Seamless onboarding of Mr. Sushobhan Dasgupta and Mr. Daniel Hayes along with other leadership team members Rev
Slide 18: Our Regional Presence
OUR REGIONAL PRESENCE Shalby has developed strong brand recognition in its core markets and is well positioned for further expansion National Presence International Presence (in Africa) PUNJAB Mohali – 145 beds RAJASTHAN Jaipur – 237 beds GUJARAT Ahmedabad o SG – 201 beds o Krishna – 220 b
Slide 19: Hospital Business Update
HOSPITAL BUSINESS UPDATE Santa Cruz Development Update Nashik Development Update Business Model: Revenue Sharing Business Model: Revenue Sharing Bed Capacity: 175 Bed Capacity: 146 Operating and Management Term: 30 + 30 years Operating and Management Term: 30 years Operationalization Year: FY 2024 O
Slide 20: SG Group - Hospital Business Update
HOSPITAL BUSINESS UPDATE Catchment: Ahmedabad and surrounding areas of Gujarat, Commencement 2007 | 13 Years Rajasthan and Mumbai No. of beds / Occupancy 201 | 34% • Q-o-Q revenue and EBIDTA witnessed a healthy recovery, SG reaching nearly 85% of the pre-COVID levels. The surgical Type of Arrangemen
Slide 21: Hospital Business Update
HOSPITAL BUSINESS UPDATE Commencement 2017 | 3 Years Catchment: South Gujarat, North Maharashtra (including Mumbai) No. of beds / Occupancy 243 | 49% Surat • 2nd wave for Covid-19 resulted in maximized capacity Type of Arrangement Freehold Surat Group • Initiated private vaccination with various Cor
Slide 22: Zynova Mohali - Hospital Business Update
HOSPITAL BUSINESS UPDATE Commencement 2017 | 2+ Years Catchment: Punjab, Uttrakhand, Haryana Mohali No. of beds / Occupancy 145 | 31% • Focus on Oncology business to enhance day care chemotherapy and bone marrow transplant Type of Arrangement Freehold • Cardiac sciences promotion for adequate utiliz
Slide 23: Sustainability Initiatives
SUSTAINABILITY INITATIVES Value creation for all our stakeholders through sustainable business practices, is at the core of Shalby Energy Conservation Waste Management Vaccination Programs Lighting automation and use of LEDS Every year we produce around 4,800 Covid-19 vaccination across units with t
Slide 24: Sustainability Initiatives
SUSTAINABILITY INITATIVES The Company remains committed on implementing sustainable best practices Environment Highlights Social Highlights Governance Highlights Plastic bag Quarterly rewards and ISO 17025 recognition policy for all. Most of Shalby Hospitals replaced with Cloud-based HR software are
Slide 25: Disclaimer and Contact Details
DISCLAIMER and CONTACT DETAILS No representation or warranty, express or implied is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of such information or opinions contained herein. The information contained in this presentation is only current as